Jane Preuss Hasselby

Jane Preuss Hasselby

Clinical Associate Professor


  1. E-pub ahead of print

    Randomized Phase II Study of Nivolumab with or Without Ipilimumab Combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

    Chen, I. M., Johansen, Julia Sidenius, Theile, S., Hjaltelin, Jessica Xin, Novitski, Sif Ingibergsdóttir, Brunak, Søren, Hasselby, Jane Preuss, Willemoe, G. L., Lorentzen, T., Madsen, K., Jensen, B. V., Wilken, E. E., Geertsen, P., Behrens, C., Nolsøe, Christian, Hermann, K. L., Svane, Inge Marie & Nielsen, Dorte Lisbet, 2022, (E-pub ahead of print) In: Journal of Clinical Oncology. JCO.21.02511.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. E-pub ahead of print

    Molecular heterogeneity of pancreatic intraductal papillary mucinous neoplasms and implications for novel endoscopic tissue sampling strategies

    Rift, Charlotte Vestrup, Melchior, L. C., Scheie, David, Hansen, C. P., Lund, Eva Løbner & Hasselby, Jane Preuss, 2022, (E-pub ahead of print) In: Journal of Clinical Pathology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)

    Theile, S., Johansen, Julia Sidenius, Nielsen, Dorte Lisbet, Jensen, B. V., Hansen, C. P., Hasselby, Jane Preuss, Eiríksson, S. V. & Chen, I. M., 2022, In: Pharmaceutics. 14, 3, 509.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 33970273